Logo

PharmaShots Weekly Snapshots (September 30 – October 04, 2024)

Share this

PharmaShots Weekly Snapshots (September 30 – October 04, 2024)

This week PharmaShots’ news was all about the updates on Clinical Trials, Pharma, Biotech, COVID-19, Regulatory & MedTech. Check out our full report below:

 

BMS Reports Data from P-IIIb/IV (PSORIATYK SCALP) and Real-World (RePhlect) Studies of Sotyktu for Moderate-to-Severe Scalp Psoriasis

Read More: BMS                                                                                                

Merus Reports the First Patient Dosing in P-III (LiGeR-HN1) Study of Petosemtamab Plus Keytruda for 1L Treatment of R/M Head and Neck Squamous Cell Carcinoma (HNSCC)

Read More: Merus                                                                        

UroGen Reports the First Patient Dosing with UGN-103 in P-III (UTOPIA) Study to Treat Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Read More: UroGen                                                                                                                 

Johnson & Johnson Highlights the Real-World Study of Erleada (Apalutamide) for Treating Metastatic Castration-Sensitive Prostate Cancer at ECOP 2024

Read More: Johnson & Johnson                                                                               

 

AbbVie Seeks the US FDA’s Accelerated Approval of Telisotuzumab Vedotin (Teliso-V) for Treating Non-Squamous NSCLC

Read More: AbbVie                                                                                 

Sanofi and Regeneron’s Dupixent Receives the US FDA’s and NMPA’s Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

Read More: Sanofi & Regeneron                                                                              

Astria Therapeutics’ Navenibart Gains the US FDA’s Orphan Drug Designation to Treat Hereditary Angioedema

Read More: Astria Therapeutics                                                                    

Johnson & Johnson Submits sBLA of Darzalex Faspro Regimen to the US FDA for Newly Diagnosed Multiple Myeloma Patients

Read More: Johnson & Johnson                                                                               

AstraZeneca and Daiichi Sankyo Report the US FDA’s sBLA Acceptance of Enhertu with Priority Review to Treat HR+/HER2-low Metastatic Breast Cancer

Read More: AstraZeneca & Daiichi Sankyo                                                              

AstraZeneca Reports the US FDA’s sNDA Acceptance of Calquence with Priority Review for Mantle Cell Lymphoma

Read More: AstraZeneca                                                                                        

Sagimet’s Denifanstat Gains the US FDA’s Breakthrough Therapy Designation to Treat Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Read More: Sagimet                                                                                                  

BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)

Read More: BMS         

                                                                                
Daiichi Sankyo Reports the sNDA Submission of Enhertu to Treat HER2 Low or Ultralow Metastatic Breast Cancer in Japan

Read More: Daiichi Sankyo                                                                                      

 

Genentech Reports the Acquisition of Regor's CDK Inhibitors Portfolio Targeting Breast Cancer

Read More: Genentech & Regor                                                                         

Recordati to Acquire Sanofi’s Enjaymo, Enhancing its Rare Diseases Portfolio

Read More: Recordati & Sanofi                                                                        

 

Prime Medicine and BMS Join Forces to Develop and Commercialize Various Prime Edited Ex Vivo T-Cell Therapies

Read More: Prime Medicine & BMS                                                                  

ABL Bio Collaborates with Merck to Develop ABL103 Plus Keytruda for Treating Solid Tumors

Read More: ABL Bio & Merck                                                                                      

 

Organon and Shanghai Henlius Biotech Provides Update on P-III Trial of HLX11 (Biosimilar, Perjeta)

Read More: Organon & Shanghai Henlius Biotech                                        

Fresenius Kabi and Formycon Report the US FDA’s Approval of Otulfi (Biosimilar, Stelara)

Read More: Fresenius Kabi & Formycon                                                           

Teva and mAbxience Join Forces on Second Biosimilar Candidate in Oncology

Read More: Teva & mAbxience                                                                    

 

Elucid Reports the US FDA’s Approval of PlaqueIQ Image Analysis Software for Cardiovascular Disease Evaluation

Read More: Elucid                                                                                             

SetPoint Medical Reports the US FDA’s IDE Approval to Initiate Neuroimmune Modulation Platform’s Evaluation for Relapsing-Remitting Multiple Sclerosis

Read More: SetPiont Medical                                                                                

OrthAlign Reports the US FDA’s Approval of Lantern Hip Technology for Hip Arthroplasty

Read More: OrthAlign                                                                                         

 

Merck Animal Health Reports the Launch of SENSEHUB Cow Calf Remote Monitoring Technology

Read More: Merck Animal Health                                                                      

Related Post: PharmaShots Weekly Snapshots (September 23 – September 27, 2024)


Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions